药易购(300937) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 1,121,966,149.54, representing a 23.29% increase compared to CNY 910,012,727.88 in the same period last year[5] - Net profit attributable to shareholders was CNY 31,632,639.16, a significant increase of 246.22% from CNY 9,136,693.85 year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY 31,478,461.26, up 363.00% from CNY 6,798,768.20 in the previous year[5] - The basic and diluted earnings per share were both CNY 0.33, reflecting a 230.00% increase from CNY 0.10 in the same quarter last year[5] - The net profit for Q1 2023 was CNY 29,507,984.82, a significant increase from CNY 7,414,416.55 in Q1 2022, representing a growth of approximately 297%[23] - The operating profit for the quarter was CNY 34,406,195.40, compared to CNY 9,579,251.88 in the same period last year, indicating a year-over-year increase of about 260%[23] - The total profit for the quarter was CNY 34,387,283.03, compared to CNY 9,656,037.25 in Q1 2022, representing an increase of about 257%[23] - The company reported a total revenue from sales of goods and services of CNY 774,388,431.08, compared to CNY 628,484,597.81 in the same quarter last year, marking an increase of approximately 23%[25] Assets and Liabilities - The company's total assets at the end of the quarter were CNY 1,615,009,586.92, a 1.47% increase from CNY 1,591,618,007.45 at the end of the previous year[5] - Accounts receivable increased by 515.42% to CNY 426,663,455.80, primarily due to sales agreements with wholesale customers[9] - The company reported a 65.19% increase in accounts payable, reaching CNY 306,515,738.89, attributed to higher sales volume[9] - The company's total assets reached ¥1,615,009,586.92, an increase from ¥1,591,618,007.45, showing overall growth[21] - Current liabilities decreased marginally to ¥748,364,046.38 from ¥752,704,099.36, suggesting improved liquidity management[20] - The equity attributable to shareholders increased to ¥843,870,160.41 from ¥813,943,586.42, reflecting a positive change in retained earnings[21] Cash Flow - Cash flow from operating activities was negative at CNY -117,143,342.26, worsening by 103.94% compared to CNY -57,440,183.26 in the same period last year[11] - The net cash flow from financing activities was negative at CNY -106,428,305.48, a decline of 2150.58% compared to CNY 5,190,145.01 in the previous year[11] - Cash and cash equivalents decreased to ¥204,724,673.38 from ¥457,824,436.55 at the beginning of the year, a decline of 55.3%[20] - Total cash and cash equivalents at the end of Q1 2023 were CNY 103,615,786.15, down from CNY 89,292,730.22 at the end of Q1 2022[27] - The cash outflow from investing activities was CNY 9,833,344.66, compared to an inflow of CNY 6,417,422.29 in the same period last year, indicating a shift in investment strategy[27] Shareholder Information - The total number of common stock shareholders at the end of the reporting period is 16,531[14] - The largest shareholder, Li Yanfei, holds 36.97% of the shares, totaling 35,370,000 shares[14] - The second-largest shareholder, Chengdu Biyuan New航创业投资基金, holds 7.11% with 6,800,000 shares[14] - The company has a total of 54,555,100 shares subject to lock-up agreements, with 93,000 shares released during the period[17] - The total number of preferred stock shareholders is not applicable, indicating no preferred shares were issued[16] - The company plans to unlock 25% of the locked shares annually for executives, with the first release scheduled for May 16, 2023[17] - The total number of shares held by the top 10 unrestricted shareholders amounts to 2,616,400 shares[14] - The total number of shares held by the top 10 shareholders with restricted shares remains unchanged at 54,462,100 shares[17] - The company has a lock-up period of 36 months for shares issued during the initial public offering[16] Credit and Impairment - The company experienced a 201.68% increase in credit impairment losses, amounting to CNY -17,887,426.87, due to increased accounts receivable[11] - The company incurred a credit impairment loss of CNY 17,887,426.87, which was higher than the loss of CNY 5,929,230.65 in the previous year[23]